Fed Governor Adriana Kugler to resign
Alignment Healthcare, Inc. (NASDAQ:ALHC), a provider of healthcare and medical service plans, has announced significant changes to its board structure and a new consulting agreement with a former board member, according to a recent SEC filing.
On Monday, two members of the company's Board of Directors, Jeffrey Margolis and Thomas Carella, tendered their resignations, effective immediately. The company clarified that their departures were not due to any disagreements regarding operations, policies, or practices.
The Board expressed appreciation for the contributions of both Margolis and Carella, who served for ten and seven years respectively, and wished them well in future endeavors.
Subsequent to these departures, the Board decided to reduce its size from eleven to nine members. Additionally, Margaret McCarthy's position was shifted from a Class I director to a Class III director, aiming to keep the number of directors in each class as equal as possible.
In conjunction with his resignation, Margolis entered into a consulting agreement with Alignment Healthcare's primary operating subsidiary. Effective from Monday, this agreement prohibits the company from terminating his services without cause before June 30, 2026.
Margolis will receive an initial payment of $18,333, followed by varying monthly retainers ranging from $9,167 to $21,667 until the end of the agreement. The consulting arrangement includes standard confidentiality and non-disparagement clauses.
In other recent news, Alignment Healthcare has displayed impressive growth in the second quarter, with a 56% increase in health plan membership and a 47% surge in revenue year-over-year.
This performance led to an upward adjustment in year-end membership expectations by 8,000 members, and the company forecasts at least 20% growth in 2025. In light of these results, Baird, TD Cowen, and Piper Sandler all raised their stock price targets for the company.
Furthermore, the company announced the immediate resignation of two board members, Thomas Carella and Jeffrey Margolis, who will transition to advisory roles, without any disagreements regarding company operations or practices. These are the recent developments that continue to make Alignment Healthcare an interesting prospect for investors.
InvestingPro Insights
As Alignment Healthcare, Inc. (NASDAQ:ALHC) navigates through its board restructuring and new consulting agreements, it's important for investors to consider the company's financial health and market performance. According to InvestingPro data, Alignment Healthcare has a market capitalization of approximately $1.65 billion. Despite a robust revenue growth of 37.46% over the last twelve months as of Q2 2024, the company's gross profit margin stands at 10.65%, which is considered weak by industry standards. This may be a contributing factor to why analysts do not anticipate the company will be profitable this year.
InvestingPro Tips suggest that investors should be aware that six analysts have revised their earnings expectations downwards for the upcoming period, indicating potential concerns about the company's future profitability. Additionally, the company has been trading at a high Price/Book multiple of 13.45, which can be a point of caution for value-focused investors.
On the brighter side, Alignment Healthcare has seen a strong return over the last three months, with the price total return at 22.89%. This positive momentum is also reflected in the six-month price total return of 29.37%. However, it's worth noting that the company does not pay dividends, which may influence the investment strategy of income-seeking shareholders.
For those interested in further details and analysis, there are additional InvestingPro Tips available at: https://www.investing.com/pro/ALHC. These tips can provide deeper insights into Alignment Healthcare's performance and potential investment opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.